Current Pharmaceutical Biotechnology

Editor-in-Chief:

Davide Prosperi
Department of Biotechnology and Bioscience
University of Milan Bicocca
Milano
Italy

Back

Become EABM
Become Reviewer

Editorial [Hot Topic: New Frontiers in Immunology and Infectious Diseases (Guest Editor: Stefan Borgmann)] promotion: free to download

Volume:13   Issue: 8
Pp: 1377-1377
Stefan Borgmann
DOI: 10.2174/138920112800784934

Dendritic Cells: Elegant Arbiters in Human Reproduction

Volume:13   Issue: 8
Pp: 1378-1384
Sabine E. Segerer, Claudia Staib, Ulrike Kaemmerer, Torsten Frambach, Arnd Honig, Johannes Dietl and Lorenz Rieger
DOI: 10.2174/138920112800784916

Monoclonal Antibodies for the Immunotherapy of Solid Tumours

Volume:13   Issue: 8
Pp: 1385-1398
Richard Mauerer and Rudolf Gruber
DOI: 10.2174/138920112800784844

Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists

Volume:13   Issue: 8
Pp: 1418-1425
Beatriz Perez-Zafrilla, Loreto Carmona and Juan J. Gomez-Reino
DOI: 10.2174/138920112800784808

Recent Advances in Active Specific Cancer Vaccine Treatment for Colorectal Cancer

Volume:13   Issue: 8
Pp: 1439-1445
Kiyotaka Okuno, Fumiaki Sugiura, Kyogo Itoh, Koji Yoshida, Takuya Tsunoda and Yusuke Nakamura
DOI: 10.2174/138920112800784998

Bacteria and their Toxins Tamed for Immunotherapy

Volume:13   Issue: 8
Pp: 1446-1473
Irena Adkins, Jana Holubova, Martina Kosova and Lenka Sadilkova
DOI: 10.2174/138920112800784835

Editorial [Hot Topic: New Treatment Strategies in Schizophrenia Beyond Dopamine: Glutamatergic Neurotransmission and More (Guest Editor: Christoph Mulert & Elizabeth Scarr)] promotion: free to download

Volume:13   Issue: 8
Pp: 1474-1475
C. Mulert
DOI: 10.2174/138920112800784871

Subjective Well-being of Patients with Schizophrenia as a Target of Drug Treatment

Volume:13   Issue: 8
Pp: 1490-1499
E. Karamatskos, C. Mulert, M. Lambert and D. Naber
DOI: 10.2174/138920112800784862

The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development

Volume:13   Issue: 8
Pp: 1500-1512
Alice Egerton and James M. Stone
DOI: 10.2174/138920112800784961

DTNBP1 (Dysbindin) Gene Variants: In Vivo Evidence for Effects on Hippocampal Glutamate Status

Volume:13   Issue: 8
Pp: 1513-1521
C. Wirth, F. Schubert, M. Lautenschlager, R. Bruhl, A. Klar, T. Majic, U. E. Lang, A. Ehrlich, G. Winterer, T. Sander, M. Schouler-Ocak and J. Gallinat
DOI: 10.2174/138920112800784952

Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Treatments

Volume:13   Issue: 8
Pp: 1522-1534
L. J. Gray, A. J. Hannan and X. Zhang
DOI: 10.2174/138920112800784817

Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia

Volume:13   Issue: 8
Pp: 1535-1542
Robert E. McCullumsmith, John Hammond, Adam Funk and James H. Meador-Woodruff
DOI: 10.2174/138920112800784899

From Glutamatergic Dysfunction to Cognitive Impairment: Boundaries in the Therapeutic of the Schizophrenia

Volume:13   Issue: 8
Pp: 1543-1548
P. A. Gaspar, M. L. Bustamante, L. E. Rojo and A. Martinez
DOI: 10.2174/138920112800784790

Disturbed Function of GABAergic Interneurons in Schizophrenia: Relevance for Medical Treatment?

Volume:13   Issue: 8
Pp: 1549-1556
J. Genius, I. Giegling, J. Benninghoff and D. Rujescu
DOI: 10.2174/138920112800784943

Treating Impaired Cognition in Schizophrenia

Volume:13   Issue: 8
Pp: 1587-1594
H. M. Ibrahim and C. A. Tamminga
DOI: 10.2174/138920112800784772

Immunological Treatment Options for Schizophrenia

Volume:13   Issue: 8
Pp: 1606-1613
Norbert Muller, Aye-Mu Myint and Markus J. Schwarz
DOI: 10.2174/138920112800784826

Current Progress in the Genetic Research of Schizophrenia: Relevance for Drug Discovery?

Volume:13   Issue: 8
Pp: 1614-1621
Dan Rujescu, Just Genius, Jens Benninghoff and Ina Giegling
DOI: 10.2174/138920112800784754

Functional Magnetic Resonance Imaging and Treatment Strategies in Schizophrenia

Volume:13   Issue: 8
Pp: 1622-1629
Susanne Karch, Oliver Pogarell and Christoph Mulert
DOI: 10.2174/138920112800784853